Company Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 500 |
| CEO | Dr. Christopher C. Gibson Ph.D. |
Contact Details
Address: 41s Rio Grande Street Salt Lake City, Utah 84101 United States | |
| Phone | (385) 269-0203 |
| Website | recursion.com |
Stock Details
| Ticker Symbol | RXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001601830 |
| CUSIP Number | 75629V104 |
| ISIN Number | US75629V1044 |
| Employer ID | 46-4099738 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Tina Marriott Larson | Chief Operating Officer and President |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder and Director |
| Dr. Michael Secora Ph.D. | Chief Financial Officer |
| Kevin Leggat | Vice President of Finance and Accounting |
| Benjamin Mabey M.S. | Chief Technology Officer |
| Jared Allenbach | Senior Director of Investor Relations |
| Nathan Hatfield | Chief Legal Officer and General Counsel |
| Ryan Kelly | Chief Communications Officer |
| Matthew Kinn | Chief Corporate Development Officer and SVice President of Business Development and Corporate Initiatives |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | 144 | Filing |
| Apr 16, 2024 | 144/A | Filing |
| Apr 16, 2024 | 144 | Filing |
| Apr 16, 2024 | 144 | Filing |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |